These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19300420)

  • 21. Renal cell carcinoma: complete response.
    Calvo OF; Vázquez DD; López MR; Aparicio LM
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S17-8. PubMed ID: 20110782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib.
    Li T; Wang L; Wang H; Zhang S; Atikan Kawuli ; Zhang X; Luo Z; Wang C
    Invest New Drugs; 2016 Dec; 34(6):701-706. PubMed ID: 27604635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
    Heng DY; Rini BI; Garcia J; Wood L; Bukowski RM
    Clin Genitourin Cancer; 2007 Dec; 5(7):446-51. PubMed ID: 18272027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelioid hemangioendothelioma of the kidney treated with sunitinib.
    Tolkach Y; Petrov S; Lerut E; Van Poppel H
    Onkologie; 2012; 35(6):376-8. PubMed ID: 22722460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.
    Ghose A; Tariq Z; Veltri S
    Am J Ther; 2012 Jan; 19(1):e56-8. PubMed ID: 20634674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous regression of metastatic renal cancer after short-term treatment with sunitinib.
    Yanagihara Y; Tanji N; Nishida T
    Int J Urol; 2011 Mar; 18(3):258-9. PubMed ID: 21332822
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of metastatic malignant fibrous histiocytoma of the kidney.
    Sugihara T; Fujimura T; Kume H; Homma Y
    Urol Int; 2010; 85(1):118-20. PubMed ID: 20516674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.
    Porzio R; Bella MA; Rossi G; Ardizzoni A
    Anticancer Res; 2013 Mar; 33(3):1061-3. PubMed ID: 23482782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
    Cowey CL; Fielding JR; Rathmell WK
    Urology; 2010 May; 75(5):1108-13.e1. PubMed ID: 19931124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA copy number changes in tumors within the spectrum of cellular, atypical, and metastasizing fibrous histiocytoma.
    Charli-Joseph Y; Saggini A; Doyle LA; Fletcher CD; Weier J; Mirza S; Vemula S; LeBoit PE
    J Am Acad Dermatol; 2014 Aug; 71(2):256-63. PubMed ID: 24755122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
    J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SU11248 and AG013736: current data and future trials in renal cell carcinoma.
    Rini BI
    Clin Genitourin Cancer; 2005 Dec; 4(3):175-80. PubMed ID: 16425985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor.
    Dudek AZ; Murthaiah PK; Franklin M; Truskinovsky AM
    Acta Oncol; 2010; 49(1):101-4. PubMed ID: 19412810
    [No Abstract]   [Full Text] [Related]  

  • 35. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM
    Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
    [No Abstract]   [Full Text] [Related]  

  • 37. Three new drugs available to fight kidney cancer.
    Bankhead C
    J Natl Cancer Inst; 2006 Sep; 98(17):1181-2. PubMed ID: 16954469
    [No Abstract]   [Full Text] [Related]  

  • 38. Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.
    Kaldrymides P; Kostoglou-Athanassiou I; Gkountouvas A; Veniou E; Ziras N
    Endocrine; 2010 Feb; 37(1):6-10. PubMed ID: 20963554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates.
    Tapiawala SN; Bargman JM; Oreopoulos DG; Simons M
    Int Urol Nephrol; 2009; 41(2):431-4. PubMed ID: 19255867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal pleomorphic undifferentiated sarcoma: a rarity.
    Kumar S; Bansal P; Tiwari P; Kundu AK
    Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1241-2. PubMed ID: 23168856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.